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INTRODUCTION 
In recent years, the use of 3D printing (3DP) for formation of custom dose forms has 
received increasing research interest for pharmaceutical applications. To date limited 
API loadings have been achieved. Current fused deposition modelling (FDM) 
approaches utilise a formulated filament (e.g. polymer and active)  as a feedstock 
which can be made by hot-melt extrusion (HME). One key purpose of this work is to 
explore methods of achieving developing a viable routes to establishing wider ranging 
API loading using HME as a filament former. 
During hot-melt extrusion establishing a viable operating space for subsequent 
formulation and processing is essential. This processing space must avoid conditions 
resulting in degradation by thermal or mechanical energy and deliver extruded filament 
with suitable properties for subsequent processing (e.g. 3D printing) 
As a first step, two pharmaceutical polymers, have been processed across the full 
operating range of a twin screw extruder (TSE) in order to identify processing space 
where degradation is likely to occur and where it can be avoided.   
As a second step, the HME process was further developed to produce up to 50:50 
wt/wt API loaded HPMC based filament of suitable character for 3DP)f dose forms by 
FDM. 
Observations of extrudate formed 
The physical appearance of the extrudates of both polymers at different processing 
temperatures (150, 180 and 210°C) and operating range of extruder speed (100  ? 1000 
rpm) are shown in Figures 1. Specific mechanical energy calculated from torque 
produced during extrusion as a function of extruder speed is shown for information in 
Figure 2.  It can be seen from the physical appearance of Affinisol ? was 
degraded/discoloured by a combined effect of screw speeds and temperature whereas 
Plasdone ? ĚŽĞƐŶ ?ƚ show any immediate discolouration.  
CONCLUSIONS 
Viable operating space for HME of Affinisol ? 15LV and  Plasdone ?-
S630 has been established. 
Methods to produce filaments with a broad range of API loading 
suitable for 3D printing by FDM has been shown. 
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Figure 1: Physical appearance of Affinisol ? ? ?>sĂŶĚPlasdone S-630 polymer extrudates 
Figure 2: Specific mechanical energy curve for A) 
Affinisol ?ĂŶĚ ?Plasdone ?^ ? ? ?
Although, Affinisol ? 15LV showed 
discoloration at higher temperature 
and/or extruder speed compared with 
Plasdone ?-S630, but Plasdone ? starts 
foaming at similar conditions.  
Establishing viable operating space for polymers 
Affinisol ? 15LV (HPMC, Dow Chemical Co.) and Plasdone ?-S630 (copovidone, Ashland) 
were extruded using a 16mm co-rotating TSE (Thermo Scientific, Karlsruhe, Germany) at 
1.0kg/hr through a die to produce an extrudate strand. Three barrel temperatures (150, 
180 and 210°C) were used and the screw speed was adjusted between 100-1000 rpm.  
From the initial experiments, it was concluded that both the Affinisiol ? 
15LV polymer and Plasdone ? were limited to lower processing speeds 
and temperature wrt both degradation in the case of Affinisiol ? and 
successful filament formation in the case of Plasdone ?. The next stage of 
the work focussed upon the use of Affinisol ? for formulating API loaded 
filaments for subsequent printing by FDM. 
For successful printing, filaments of Ø = 1.75 mm ±0.05 mm, must be 
formulated.  
To produce Affinisol ? filaments for 3DP using HME, variables such as die 
type, extruder speed and downstream conveyor speed were varied to 
develop knowledge and enable some degree of process optimisation. 
Figure 3a shows examples of the overall range of filament sizes of 
Affinisol ? that can be produced within the viable operating space (i.e. 
temp and mechanical energy) developed earlier. Figure 3b shows 
examples of the level of filament diameter control across a range of 
polymer : API formulations which were then subsequently printed.  
 
Examples of  some basic analysis of 10-50% API loaded 3D printed dose 
forms are shown below. 
Figure 3: a) Diameter of HPMC Affinisol ?ĞǆƚƌƵĚĞĚĨŝůĂŵĞŶƚƐƵƐŝŶŐǀĂƌŝŽƵƐĚŝĞƚǇƉĞƐ ?
b) Diameter of the filament in addition with API (%) during extrusion 
a b 
Figure 4: a) X-ray diffractogram of the 3D printed tablets in comparison with  
extrudates and physical blend of the bulk API and polymer, b) Drug release studies 
Amorphous state of the API was observed in all 3D printed tablets and 
also in the extruded pellets (Figure 4a) except the higher API loaded 
tablets and from the dissolution studies (Figure 4b), extended drug 
release pattern has been observed. 
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